MarketCap
Facebook
X
Telegram
Ovid Therapeutics EBITDA | OVID
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Ovid Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -42.2 M | -61.3 M | -58.7 M | -55 M | 124 M | -81.1 M | -61.2 M | -52.8 M | -64.9 M | -22.5 M | -13.2 M | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 124 M | -81.1 M | -35.3 M |
Quarterly EBITDA Ovid Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -22.4 M | -15.7 M | -17.8 M | -12.3 M | -12.5 M | -5.04 M | -12.5 M | -10.7 M | -13.2 M | -20.5 M | -17.4 M | -18.2 M | -12 M | -14.1 M | -14.9 M | - | -12.7 M | -14.3 M | -16.2 M | -26.3 M | -11.6 M | -14.3 M | 177 M | -21.5 M | -16.3 M | -23.1 M | -20.2 M | -17.2 M | -16.7 M | -13.3 M | -14 M | - | -13.1 M | -13.2 M | -13.4 M | - | -9.35 M | -10.3 M | -34.2 M | - | -5.79 M | -5.4 M | 5.9 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 177 M | -34.2 M | -9.87 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AIM ImmunoTech
AIM
|
-11.6 M | $ 0.15 | 6.3 % | $ 243 K |  USA |
 |
MediWound Ltd.
MDWD
|
-8.73 M | $ 13.81 | -2.13 % | $ 376 M |  Israel |
 |
Ascendis Pharma A/S
ASND
|
-136 M | $ 258.99 | 0.94 % | $ 15.7 B |  Danmark |
 |
ANI Pharmaceuticals
ANIP
|
203 M | $ 71.09 | -0.22 % | $ 1.43 B | USA |
 |
Actinium Pharmaceuticals
ATNM
|
-36.1 M | $ 1.59 | 1.27 % | $ 49.6 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-262 M | $ 1.24 | -6.06 % | $ 330 M |  Britain |
 |
BridgeBio Pharma
BBIO
|
-518 M | $ 79.53 | 1.09 % | $ 15.2 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
342 M | $ 7.66 | 1.73 % | $ 1.61 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
-241 M | $ 3.69 | -0.14 % | $ 256 M | Britain |
 |
Coherus BioSciences
CHRS
|
-180 M | $ 0.58 | -8.97 % | $ 67.9 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-11.5 M | $ 28.37 | 3.6 % | $ 3.61 B | USA |
 |
Cellectis S.A.
CLLS
|
-33.1 M | $ 1.35 | 21.62 % | $ 135 M |  France |
 |
BeyondSpring
BYSI
|
-8.86 M | $ 0.64 | 10.75 % | $ 26.3 M | USA |
 |
Alkermes plc
ALKS
|
281 M | $ 47.94 | 3.16 % | $ 7.9 B |  Irlanda |
 |
Altimmune
ALT
|
-94.4 M | $ 1.94 | -0.21 % | $ 171 M | USA |
 |
Cardiff Oncology
CRDF
|
-48.6 M | $ 0.76 | -4.57 % | $ 50.8 M | USA |
 |
Novartis AG
NVS
|
17.6 B | $ 160.35 | -1.79 % | $ 311 B |  Schweiz |
 |
Citius Pharmaceuticals
CTXR
|
-38.5 M | $ 0.49 | -1.36 % | $ 5.42 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-73.2 M | $ 9.32 | -0.75 % | $ 255 M | Israel |
 |
Arrowhead Pharmaceuticals
ARWR
|
121 M | $ 49.35 | 0.71 % | $ 6.6 B | USA |
 |
Atara Biotherapeutics
ATRA
|
38 M | $ 8.27 | 2.1 % | $ 104 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
52.7 M | $ 16.22 | -0.49 % | $ 2.18 B |  Canada |
 |
Cullinan Management
CGEM
|
-241 M | $ 11.33 | 0.89 % | $ 683 M | USA |
 |
BioNTech SE
BNTX
|
-1.4 B | $ 87.68 | 0.54 % | $ 21.2 B |  Germany |
 |
Collegium Pharmaceutical
COLL
|
64.9 M | $ 24.8 | 1.35 % | $ 785 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-85.1 M | $ 3.99 | 1.53 % | $ 53.1 M | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
-14.7 M | $ 1.24 | 3.33 % | $ 56.7 M | Israel |
 |
AnaptysBio
ANAB
|
32.3 M | $ 48.73 | 0.72 % | $ 1.41 B | USA |
 |
Assembly Biosciences
ASMB
|
-12 M | $ 22.36 | 4.73 % | $ 251 M | USA |
 |
Adagene
ADAG
|
-21 M | $ 2.14 | 4.39 % | $ 126 M |  China |
 |
Benitec Biopharma
BNTC
|
-51.1 M | $ 9.47 | 2.05 % | $ 441 M | USA |
 |
Denali Therapeutics
DNLI
|
-544 M | $ 19.74 | -0.55 % | $ 3.41 B | USA |
 |
Amarin Corporation plc
AMRN
|
-47.1 M | $ 11.68 | -0.64 % | $ 4.85 B | Irlanda |
 |
ImmuCell Corporation
ICCC
|
4.43 M | $ 10.19 | -0.7 % | $ 92 M | USA |
 |
Editas Medicine
EDIT
|
-155 M | $ 2.38 | -4.99 % | $ 211 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
-467 M | $ 32.84 | 3.38 % | $ 1.9 B | USA |
 |
Cue Biopharma
CUE
|
-25.6 M | $ 19.08 | 1.71 % | $ 1.81 B | USA |
 |
Equillium
EQ
|
-23.5 M | $ 1.41 | -3.09 % | $ 80.8 M | USA |
 |
Black Diamond Therapeutics
BDTX
|
12.8 M | $ 1.61 | 0.63 % | $ 91.6 M | USA |
 |
Abeona Therapeutics
ABEO
|
-86.9 M | $ 2.35 | -4.28 % | $ 124 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
106 M | $ 18.38 | 0.55 % | $ 3.09 B | USA |
 |
PainReform Ltd.
PRFX
|
-5.11 M | $ 0.74 | -6.69 % | $ 480 K | Israel |
 |
Atossa Therapeutics
ATOS
|
-37.1 M | $ 2.04 | -4.67 % | $ 17.6 M | USA |
 |
Cleveland BioLabs, Inc.
CBLI
|
-2.58 M | - | -7.31 % | $ 49 M | USA |
 |
PDS Biotechnology Corporation
PDSB
|
-31.5 M | $ 1.01 | -1.46 % | $ 46.8 M | USA |
 |
Five Prime Therapeutics, Inc.
FPRX
|
-87 M | - | - | $ 1.77 B | USA |
 |
ADC Therapeutics SA
ADCT
|
-121 M | $ 1.6 | 5.3 % | $ 203 M | Schweiz |
 |
Harmony Biosciences Holdings
HRMY
|
232 M | $ 34.22 | 2.0 % | $ 1.97 B | USA |
 |
Ardelyx
ARDX
|
-37.9 M | $ 3.14 | 4.15 % | $ 757 M | USA |
 |
Akebia Therapeutics
AKBA
|
24.8 M | $ 0.57 | 5.2 % | $ 147 M | USA |